Navigation Links
Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
Date:10/22/2007

PASADENA, Calif., Oct. 22 /PRNewswire/ -- Maven Biotechnologies, LLC, an early stage biotechnology company developing a label-free multiplexing immunodiagnostic analysis system, today announced that the company will deliver a presentation at the BIOCOM Investor Conference in San Diego, California. Jeffrey C. Travis, Ph.D., Maven's President and COO, will present on Thursday, November 1, 2007 at 3:30 PM.

About Maven Biotechnologies

Maven Biotechnologies, LLC has developed LFIRE(TM) (Label-Free Internal Reflection Ellipsometry) which is a complete diagnostics analysis system (instruments and disposables) that provides a next generation replacement measurement technology with significant cost benefits to the healthcare sector and technology improvements for the combined $15 B w/w immunodiagnostic markets. It offers the potential advantages of 50-75% reduced costs to both the diagnostics manufacturers and the clinical or pharma lab user. In addition, its breakthrough new way to measure immunodiagnostic tests more rapidly will positively impact point-of-care (POC) tests for emergency room screening (e.g. cardiac markers, drugs of abuse, etc.), at patient bedside, and in the O.R. Finally, it uniquely permits single to high density label-free multiplexing -- that is, when one to large numbers of tests per patient can be run at one time (e.g. tumor markers, autoimmune panels, etc.), greatly reducing costs for the patients, healthcare provider and importantly, the medical insurance industry. LFIRE(TM) is an enabling technology for more cost effective patient profiling of multiple tests for diagnosis, staging of disease and choice of targeted drug therapy, all key elements required for the medical industry's personalized medicine initiative. Most significantly, the market infrastructure for this technology already exists in the worldwide diagnostics and pharma industries and market penetration for this improved next generation, markedly cost effective, replacement measurement technology will be rapid. The Company is now planning development for the first commercial versions of LFIRE(TM), with planned market launch later in 2008.

http://www.mavenbiotech.com


'/>"/>
SOURCE Maven Biotechnologies, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can ... adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect ... SalivaLab , the relationship between insulin and other relevant biomarkers can be extensively ...
(Date:2/23/2017)... and SAN FRANCISCO , Feb. 23, ... medicine company, and Beyond Type 1, a not-for-profit advocacy ... diabetes, today announced a grant from Beyond Type 1 ... for type 1 and other insulin-requiring diabetes.  ... developing innovative stem cell-derived cell replacement therapies with a ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader in Atomic ... all SPIE attendees and Park customers on Feb. 27, 2017 from 12-2pm ... Jose Convention Center. The luncheon will feature a talk on Automated AFM for ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
Breaking Biology News(10 mins):